Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 2:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 547 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Intravenous Infusions Clear all
Completed Phase 1 Interventional

Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors

NCT01391533
View directory record Official record
Conditions
Malignant Solid Tumors
Interventions
SAR125844
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 12, 2016 · Synced Sep 7, 2026, 2:47 PM EDT
Completed Not applicable Interventional

Continuous High-Dose Intravenous Dextran Sulfate in Human Immunodeficiency Virus-Infected Individuals

NCT00000684
View directory record Official record
Conditions
HIV Infections
Interventions
Dextran sulfate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1991
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Sep 7, 2026, 2:47 PM EDT
Suspended Phase 2 Interventional

Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia

NCT04912115
View directory record Official record
Conditions
Dyskinesias, Movement Disorders, Central Nervous System Diseases, Nervous System Diseases, Neurologic Manifestations
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
PharmaTher Inc.
Industry
Eligibility
30 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
7
States / cities
Tucson, Arizona • Chula Vista, California • Fountain Valley, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Sep 7, 2026, 2:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of Intravenous (IV) Infusion of MTP-131 (Bendavia™) in Healthy Adults

NCT01115920
View directory record Official record
Conditions
Healthy
Interventions
MTP-131 (Bendavia™)
Drug
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 17, 2010 · Synced Sep 7, 2026, 2:47 PM EDT
Completed Phase 2 Interventional Results available

Liver Resection and Floxuridine Plus Fluorouracil and Leucovorin in Treating Patients With Liver Metastases From Colorectal Cancer

NCT00002842
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
floxuridine, fluorouracil, leucovorin calcium, adjuvant therapy, conventional surgery
Drug · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2014
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Sep 7, 2026, 2:47 PM EDT
Enrolling by invitation No phase listed Observational

Effects of Social Determinants of Health on IV Iron Treatments

NCT06591182
View directory record Official record
Conditions
Social Determinants of Health (SDOH)
Interventions
Survey using a questionnaire.
Other
Lead sponsor
BayCare Health System
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Sep 7, 2026, 2:47 PM EDT
Terminated Phase 2Phase 3 Interventional

A Study to Evaluate the Effects of ONO-2506 Intravenous Infusion in Patients With Acute Ischemic Stroke

NCT00046761
View directory record Official record
Conditions
Cerebrovascular Accident
Interventions
ONO-2506
Drug
Lead sponsor
Ono Pharma USA Inc
Industry
Eligibility
18 Years and older
Enrollment
1,320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
130
States / cities
Birmingham, Alabama • Berkeley, California • La Mesa, California + 102 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2012 · Synced Sep 7, 2026, 2:47 PM EDT
Completed Phase 1 Interventional

Safety and Tolerability Study of IV ST266 in COVID-19 Subjects

NCT04720378
View directory record Official record
Conditions
Cytokine Release Syndrome
Interventions
ST266
Biological
Lead sponsor
Noveome Biotherapeutics, formerly Stemnion
Industry
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Clearwater, Florida • Chicago, Illinois • Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Sep 7, 2026, 2:47 PM EDT
Completed Phase 3 Interventional Results available

Efficacy of Intranasal Fentanyl at Reducing Pain During Abscess Incision and Drainage (I&D) in Children

NCT01549002
View directory record Official record
Conditions
Abscess, Pain
Interventions
Intranasal Fentanyl, Intravenous Morphine
Drug
Lead sponsor
Columbia University
Other
Eligibility
4 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Sep 7, 2026, 2:47 PM EDT
Completed Phase 2 Interventional Results available

PRO 140 by IV Administration in Adults With HIV-1 Infection

NCT00613379
View directory record Official record
Conditions
HIV Infections
Interventions
PRO 140, Placebo
Drug
Lead sponsor
CytoDyn, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Sep 7, 2026, 2:47 PM EDT
Terminated Phase 2 Interventional Results available

Phase II Study of TAS-109 to Treat Advanced Colorectal Cancer

NCT00824161
View directory record Official record
Conditions
Advanced Colorectal Cancer
Interventions
TAS-109
Drug
Lead sponsor
Taiho Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
East 34th Street, New York, New York • Holcombe Boulevard, Houston, Texas • West Magnolia Avenue, Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2012 · Synced Sep 7, 2026, 2:47 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

7 Day Continuous Parathyroid Hormone IV Infusion

NCT00377312
View directory record Official record
Conditions
Osteoporosis, Bone Diseases, Endocrine, Hyperparathyroidism
Interventions
Parathyroid Hormone (1-34)
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
24 Years to 35 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Sep 7, 2026, 2:47 PM EDT
Completed Phase 1 Interventional

A Multiple Ascending Dose Study of R1507 in Children and Adolescents With Advanced Solid Tumors.

NCT00560144
View directory record Official record
Conditions
Neoplasms
Interventions
RG1507
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 17 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
6
States / cities
Tucson, Arizona • Denver, Colorado • Bethesda, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2016 · Synced Sep 7, 2026, 2:47 PM EDT
Completed Phase 2 Interventional

A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung

NCT00998192
View directory record Official record
Conditions
Metastatic or Recurrent Squamous Cell Carcinoma of the Lung
Interventions
REOLYSIN, Paclitaxel, Carboplatin
Biological · Drug
Lead sponsor
Oncolytics Biotech
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
17
States / cities
Los Angeles, California • Ocala, Florida • Niles, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2016 · Synced Sep 7, 2026, 2:47 PM EDT
Completed Phase 4 Interventional Results available

Subcutaneous Rehydration Compared to Intravenous Rehydration

NCT00773175
View directory record Official record
Conditions
Dehydration
Interventions
recombinant human hyaluronidase
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
30 Days to 10 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
25
States / cities
Hartford, Connecticut • Orlando, Florida • Tampa, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Sep 7, 2026, 2:47 PM EDT
Completed No phase listed Observational

Early Mobilization of Ischemic Stroke Patients Within 24-hours After Intravenous-Tissue Plasminogen Activator (IV-tPA)

NCT01331200
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 26, 2013 · Synced Sep 7, 2026, 2:47 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of BAX 888 in Male Adults With Severe Hemophilia A

NCT03370172
View directory record Official record
Conditions
Hemophilia A
Interventions
BAX 888
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
8
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 7, 2026, 2:47 PM EDT
Completed Phase 2 Interventional

S0301 Cyclosporine, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

NCT00066794
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, sargramostim, cyclosporine, cytarabine, daunorubicin hydrochloride
Biological · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
56 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
97
States / cities
Mobile, Alabama • Tucson, Arizona • Orange, California + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Sep 7, 2026, 2:47 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.

NCT07511205
View directory record Official record
Conditions
Healthy Participants, Obesity
Interventions
AZD1043, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 7, 2026, 2:47 PM EDT
Terminated Phase 1 Interventional

Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis

NCT04807972
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
ABBV-927, Budiglimab, modified FOLFIRINOX
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Aurora, Colorado • Baltimore, Maryland • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Sep 7, 2026, 2:47 PM EDT
Completed Not applicable Interventional Results available

Ketamine: Comparison of IV Push vs. IV Drip

NCT02363270
View directory record Official record
Conditions
Pain
Interventions
Ketamine
Procedure
Lead sponsor
Antonios Likourezos
Other
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Nov 21, 2017 · Synced Sep 7, 2026, 2:47 PM EDT
Completed Phase 2 Interventional

Safety and Effectiveness of Topotecan HCl to Treat HIV-Infected Patients With AIDS-Related Progressive Multifocal Leukoencephalopathy (PML)

NCT00002395
View directory record Official record
Conditions
HIV Infections, Leukoencephalopathy, Progressive Multifocal
Interventions
Topotecan
Drug
Lead sponsor
SmithKline Beecham
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 7, 2026, 2:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Study of PRX003 in Healthy Subjects

NCT02458677
View directory record Official record
Conditions
Psoriasis
Interventions
PRX003, Placebo
Drug · Other
Lead sponsor
Prothena Biosciences Limited
Industry
Eligibility
21 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2016 · Synced Sep 7, 2026, 2:47 PM EDT
Completed Phase 1 Interventional Results available

First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.

NCT04535167
View directory record Official record
Conditions
Viral Disease
Interventions
PF-07304814, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 79 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Mountain View, California • Newport Beach, California • Sacramento, California + 2 more
Source: ClinicalTrials.gov public record
Updated May 2, 2023 · Synced Sep 7, 2026, 2:47 PM EDT